Mexico · Delayed Price · Currency is MXN Recursion Pharmaceuticals Statistics
Total Valuation
BMV:RXRX has a market cap or net worth of MXN 44.67 billion. The enterprise value is 34.16 billion.
| Market Cap | 44.67B |
| Enterprise Value | 34.16B |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 514.90M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +63.30% |
| Shares Change (QoQ) | +7.10% |
| Owned by Insiders (%) | 3.25% |
| Owned by Institutions (%) | 60.82% |
| Float | 503.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 55.74 |
| PB Ratio | 2.33 |
| P/TBV Ratio | 4.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.60 |
| EV / Sales | 42.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.16 |
Financial Position
The company has a current ratio of 4.60, with a Debt / Equity ratio of 0.08.
| Current Ratio | 4.60 |
| Quick Ratio | 4.40 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.18 |
| Interest Coverage | -294.74 |
Financial Efficiency
Return on equity (ROE) is -91.06% and return on invested capital (ROIC) is -51.24%.
| Return on Equity (ROE) | -91.06% |
| Return on Assets (ROA) | -42.04% |
| Return on Invested Capital (ROIC) | -51.24% |
| Return on Capital Employed (ROCE) | -57.46% |
| Revenue Per Employee | 1.00M |
| Profits Per Employee | -16.41M |
| Employee Count | 800 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.73M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 98.32 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 46.18 |
| Average Volume (20 Days) | 29,851 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.40 |
Income Statement
In the last 12 months, BMV:RXRX had revenue of MXN 801.35 million and -13.12 billion in losses. Loss per share was -32.72.
| Revenue | 801.35M |
| Gross Profit | -9.23B |
| Operating Income | -13.12B |
| Pretax Income | -13.13B |
| Net Income | -13.12B |
| EBITDA | -11.70B |
| EBIT | -13.12B |
| Loss Per Share | -32.72 |
Balance Sheet
The company has 12.10 billion in cash and 1.51 billion in debt, giving a net cash position of 10.59 billion.
| Cash & Cash Equivalents | 12.10B |
| Total Debt | 1.51B |
| Net Cash | 10.59B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 19.20B |
| Book Value Per Share | 39.05 |
| Working Capital | 10.25B |
Cash Flow
In the last 12 months, operating cash flow was -8.09 billion and capital expenditures -119.65 million, giving a free cash flow of -8.21 billion.
| Operating Cash Flow | -8.09B |
| Capital Expenditures | -119.65M |
| Free Cash Flow | -8.21B |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,636.68% |
| Pretax Margin | -1,638.15% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BMV:RXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -63.30% |
| Shareholder Yield | -63.30% |
| Earnings Yield | -29.38% |
| FCF Yield | -18.38% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMV:RXRX has an Altman Z-Score of 0.75 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.75 |
| Piotroski F-Score | 2 |